Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Google Secures Pentagon AI Deal for Classified Projects 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
CAMBRIDGE, Mass., Feb. 10, 2016 -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the global collaboration agreement executed by the Company on January 8, 2016 with Mylan N.V.’s subsidiary, Mylan Ireland Limited, to develop and commercialize six biosimilar candidates.
With the early termination of the applicable waiting period under the HSR Act, the collaboration agreement with Mylan is effective as of February 9, 2016. Under the collaboration agreement, Mylan is obligated to pay Momenta a $45 million upfront cash payment within 30 days of the effective date.
Additional details regarding the collaboration can be found in Momenta’s Form 8-K filed with the Securities and Exchange Commission on January 8, 2016.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
MOMENTA INVESTOR CONTACT: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected] MOMENTA MEDIA CONTACT: Karen Sharma MacDougall Biomedical Communications 1-781-235-3060 [email protected]
